Clinical Trials on Severe covid19

Total 11639 results

Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Singapore
Sanofi Pasteur, a Sanofi Company
United States Department of Defense

Completed

Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
National Institute of Allergy and Infectious Diseases...
Johns Hopkins Bloomberg School of Public Health

Completed

Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus

Dengue Hemorrhagic Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Dengue | Dengue Hemorrhagic Fever

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America

Dengue | Dengue Hemorrhagic Fever

Brazil
Mahidol University

Completed

Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients (PKIDEN)

Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine

Yellow Fever | Dengue | Dengue Fever | Dengue Hemorrhagic Fever

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Indonesia, Philippines, Malaysia, Thailand, Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Dengue Fever | Dengue Haemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia

Dengue Fever | Dengue Hemorrhagic Fever

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Puerto Rico, Brazil, Honduras, Mexico
U.S. Army Medical Research and Development Command
GlaxoSmithKline

Completed

A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Shock Syndrome

Puerto Rico
Sanofi

Completed

A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers

Yellow Fever | Dengue | Dengue Hemorrhagic Fever

Peru, Colombia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age

Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Brazil, Colombia, Honduras, Mexico, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi

Completed

Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

United States
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Puerto Rico, Colombia, Mexico, Honduras
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Recruiting

Role of Vitamin D in Prevention of Dengue Haemorrhagic Fever and Dengue Shock Syndrome

Dengue Fever

Bangladesh
Institut Pasteur

Completed

Longitudinal Follow-up of a Population Cohort in a French City With High SARS-CoV-2 Circulation, in Early 2020 [COVID-19] (COVID-OISE)

Covid19 | SARS (Severe Acute Respiratory Syndrome)

France
Pine Trees, Inc.
Piedmont Healthcare; ICON plc; MRI Global; ASCLEPES Research Center; Eastside Research... and other collaborators

Completed

A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Test for Point-of-Care

Covid19 | SARS (Severe Acute Respiratory Syndrome)

United States
Applied Biology, Inc.

Completed

Proxalutamide Treatment for Hospitalized COVID-19 Patients

Covid19 | SARS (Severe Acute Respiratory Syndrome)

Brazil
Ministry of Public Health, Argentina

Completed

Ivermectin Reproposing for Mild Stage COVID-19 Outpatients (IVER-Leve)

Covid19 | SARS (Severe Acute Respiratory Syndrome)

Argentina
Applied Biology, Inc.

Withdrawn

Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit

Covid19 | SARS (Severe Acute Respiratory Syndrome)

Brazil
B. Braun Melsungen AG
CeGaT GmbH

Completed

Differences in Exhaled Breath by Using Ion Mobility Spectrometry (IMS) in Subjects Tested for SARS-CoV-2 Infection (COVID-19 Disease)

Covid19 | SARS (Severe Acute Respiratory Syndrome)

Germany
Maria de los Angeles Peral de Bruno

Completed

Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan (Ivercar-Tuc)

Covid19 | SARS (Severe Acute Respiratory Syndrome)

Argentina
ANRS, Emerging Infectious Diseases
Institut National de la Santé Et de la Recherche Médicale, France; University... and other collaborators

Recruiting

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection (COVERAGE-A)

Covid19 | SARS-CoV2 Infection | Severe Acute Respiratory Syndrome Coronavirus 2 | Covid19 Drug Treatment

Burkina Faso, Guinea
Oxford University Clinical Research Unit, Vietnam
Children's Hospital Number 1, Ho Chi Minh City, Vietnam; Hospital for Tropical... and other collaborators

Completed

Laboratory Diagnosis and Prognosis of Severe Dengue

Dengue Fever

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Disease

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Peru
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Efficacy and Safety of Dengue Vaccine in Healthy Children

Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus | Dengue Diseases

Thailand
University of Cagliari

Completed

Seroprevalence of SARS-Cov-2 in the Setting of a Non-dedicated COVID-19 Hospital in a Low CoV-2 Incidence Area: Implications for Surgery

Covid19 | Surgery | SARS (Severe Acute Respiratory Syndrome)

Italy
National University Hospital, Singapore
Tan Tock Seng Hospital; Ng Teng Fong General Hospital

Completed

Prospective Study for the Evaluation of Dengue Prognostic Biomarkers in Singapore

Dengue Hemorrhagic Fever | Severe Dengue | Dengue Shock Syndrome

Singapore
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus

Dengue Hemorrhagic Fever | Dengue Shock Syndrome

United States
University of Sao Paulo

Recruiting

Home-based Exercise in COVID-19 Survivors

Covid19 | SARS-CoV Infection | SARS (Severe Acute Respiratory Syndrome)

Brazil
Bangabandhu Sheikh Mujib Medical University, Dhaka...
Anwar Khan Mordern Medical College and Hospital, Dhaka; Mugda Medical College...

Unknown

Role of Co-trimoxazole in Severe COVID-19 Patients

Covid19 | Severe COVID-19 Patients

Bangladesh
Lucira Health Inc

Completed

A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion

Covid19 | Corona Virus Infection | SARS (Severe Acute Respiratory Syndrome)

United States
University of the Philippines
World Health Organization; University of North Carolina; International Vaccine... and other collaborators

Active, not recruiting

Dengue Serostatus Study in the Philippines

Dengue | Dengue Fever | Severe Dengue | Virologically-confirmed Dengue
International Brain Research Foundation

Withdrawn

Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Covid19 | SARS (Severe Acute Respiratory Syndrome)

Clinical Trials on Severe covid19

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations